Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business
- Clinical trial with HDP-101 continues with adjusted protocol and larger number of study sites in Europe
- Patient from 3rd cohort continues to be dosed and shows stable disease
- Partnership with Magenta terminated due to clinical events and strategy change at Magenta
- Walter Miller appointed Chief Financial Officer
- Financials in line with plan
- Divestment of minority stake in Emergence leads to higher cash inflows
Heidelberg Pharma AG published today its financial report on the first six months of 2023 (1 December 2022 – 31 May 2023).